T-705 as a Potential Therapeutic Agent for Rabies

Journal of Infectious Diseases

Volumn 214, Issue 3, 2016, Pages 502-503

  Virojanapirom, Phatthamon ^a   Lumlertdacha, Boonlert ^b   Wipattanakitchareon, Aschariya ^a   Hemachudha, Thiravat ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; RABIES VACCINE;

ANTIVIRAL ACTIVITY; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; EBOLAVIRUS; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS; LETTER; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RABIES; RABIES VIRUS; SURVIVAL RATE; WEST NILE VIRUS; IMMUNOLOGY;

RABIES; RABIES VACCINES; RABIES VIRUS;

EID: 84981186727     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw174     Document Type: Letter

References (4)

1. Hemachudha T, Ugolini G, Wacharapluesadee S, et al. Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol 2013; 12:498-513.
2. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446-54.
3. Oestereich L, Lüdtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014; 105:17-21.
4. Yamada K, Noguchi K, Komeno T, et al. Efficacy of favipiravir (T-705) in rabies post-exposure prophylaxis. J Infect Dis 2015; 213:1253-61.